April 15th, 2011 Press Release Briefingwire.com -- Immune Response BioPharma Prepares For Phase 1 Clinical Trials of Sepsicillin Announces Dr. Larosa of Brown University will Likely Handle Initial Phase 1 Testing of BPI Formulation Sepsicillin.
Immune Response BioPharma, Fredericksburg, Virginia Today 4/15/2011 privately held, IRBP is bringing a Biotech Boom to Virginia, Prepares for Phase 1 Clinical Trials of Sepsicillin announces Dr. Steven Larosa of Brown University and infectious disease at Rhode Island Hospital http://research.brown.edu/myresearch/Steven_LaRosa will likely head initial clinical testing of IRBP’s proprietary BPI formulation Sepsicillin for sepsis treatment when we reach that milestone. Sepsicillin is a first in class and best in class drug; a BPI based proprietary antibiotic formulation for the treatment of sepsis. IRBP still must file an IND and receive approval from the FDA to allow the company to begin moving forward with the sepsis drug.
“Today we are talking about preventing the next cardiac event. I thank Dr. Larosa for his quick response and responsible actions indicating his desire to be lead clinical investigator for Sepsicillin the job is his. Dr. Larosa is an expert on the infectious disease area and is very high on the BPI technology and knows the value of a strong antibiotic formulation that he needs to treat his patients with and save lives. I have sent word to our friends at Catalent to inquire into manufacturing of IRBP’s proprietary BPI formulation Sepsicillin to get the ball rolling on the sepsis drug. I am moving faster than I anticipated on the sepsis drug formulation as Dr. Larosa needs the drug asap to save lives” Mr. Buswell Chief Operating Officer.
“IRBP’s pipeline is further solidified with our new sepsis drug Sepsicillin, I will be reaching out to potential clinical partners and investors to secure funding for the new sepsis drug. I am in the process of building a world class BioPharmaceutical company the new Immune Response will be leaner, more agile, bigger, better, and profitable. It may take some time to secure funding and garner support for the project but there is no price you can put on saving lives. Potential clinical partners who wait to partner with IRBP will likely lose out. It is of vital importance in saving lives that doctors like Dr. Larosa have new and powerful antibiotics at their disposal to save lives” Mr. Buswell Chief Operating Officer.
Immune Response BioPharma is a diversified biopharmaceutical company engaged in the process of developing lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. The company has a deep pipeline of experimental drugs it plans to develop. Plans to raise capital is neither an offer nor solicitation for sale of securities. Safe Harbor disclosure. Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
Media Contact Info Info@immuneresponsebiopharma.com
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va
